Retrospective analysis of Sliding Scale versus Basal Bolus Insulin in the treatment of uncontrolled hyperglycemia in patients with Type 2 diabetes mellitus and infections

Basal Bolus Insulin (BBI) and Sliding Scale Insulin (SSI) regimens are the two choices for managing uncontrolled hyperglycemia in patients with Type 2 diabetes mellitus (T2DM).

We aimed to compare the glycemic control achieved and the duration of infection recovery in hospitalized Type 2 Diabetic patients with infections treated with SSI and BBI regimens.

A retrospective comparative study was performed for 6 months; a total of 126 patients were divided into 2 groups, the SSI group (n = 63) and the BBI group (n = 63). Fasting Blood Glucose (FBG) levels and duration of antibiotic therapy during hospitalization were used to assess glycemic control and infection recovery duration, respectively.

On the first day, the mean FBG values were 244.75 ± 81.72 in the BBI group and 191.21 ± 90.45 in the SSI group. On the last day, these values decreased to 159.40 ± 79.31 in the BBI group and 167.21 ± 61.81 in the SSI group. The statistical analysis revealed a significant improvement in glycemic control within the BBI group (p < 0.001), while in the SSI group, a statistically significant improvement in glycemic control was not achieved (p = 0.106).

Better glycemic control was seen in the BBI group and overall infection recovery duration was lesser in the SSI group than BBI group.